Shanghai Hile Bio-Technology Co., Ltd.
603718.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.99B
Close$
$1.71
43.5% downside
Current Fair Value
43.5% downsideOvervalued by 43.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.99 Billion |
|---|---|
| Enterprise Value | $1.95 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | 0.26 |
| Outstanding Shares | 648,979,700 |
Return
| Return on Equity | -35.64% |
|---|---|
| Return on Assets | -23.07% |
| Return on Invested Capital | -17.01% |
Valuation & Multiples
| P/E Ratio | -6.13 |
|---|---|
| PEG | 20.29 |
| Price to Sales | - |
| Price to Book Ratio | 3.03 |
| Enterprise Value to Revenue | 9.11 |
| Enterprise Value to EBIT | -9.95 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Hile Bio-Technology Co., Ltd.
340 employees
CEO: Ben Yi Han Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tis...